DOT1L and acute myeloid leukemia: In vitro studies have shown that DOT1L inhibitors induce both morphological (decreased nucleus to cytoplasm ratio, indented nuclei, less basophilic and vacuolated cytoplasm) and molecular (CD11b induction) signs of myeloid differentiation in such AML cells [186,187,188].